FDAnews
www.fdanews.com/articles/101497-nventa-provides-update-in-hspe7-trial

Nventa Provides Update in HspE7 Trial

November 27, 2007

Nventa Biopharmaceuticals has completed the assessment for safety and tolerability in a Phase I trial of new HspE7 in patients with cervical intraepithelial neoplasia (CIN).

The evaluation was performed when the first group of patients reached five weeks of treatment. The safety data from new HspE7 met the limits prescribed in the trial protocol, allowing progression to the second group of patients who will receive HspE7 with an escalated dose of adjuvant, Nventa said.

The trial is expected to dose up to five groups and include 24 patients. Four groups will be administered 500 mcg of HspE7 and doses of 50, 500, 1,000 or 2,000 mcg of adjuvant containing Poly-IC, a toll-like receptor-3 agonist.

Following successful completion of the trial, the company anticipates launching a Phase II trial in patients with high-grade CIN and a potential Phase II trial in patients that are HIV-positive with low-grade CIN.